Clinical Trials Directory

Trials / Completed

CompletedNCT01814423

Pharmacokinetic Study of Multi-dose Chloroquine

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Bandim Health Project · Academic / Other
Sex
All
Age
2 Years – 9 Years
Healthy volunteers
Not accepted

Summary

Chloroquine (CQ) remains an alternative cheap, safe and widely available drug. Our previous research has shown that double (50 mg/kg) standard dose CQ given in split doses had a 95% efficacy and was well tolerated and safe. Still, safety could be an issue when the dose of CQ is increased. Severe adverse events are caused by high peak concentrations of CQ. Using split doses of CQ avoids high peak concentrations enabling the safe administration of high doses, however, pharmacokinetic data are lacking. Children included in the study will be given 50 mg/kg as split doses over 3 days or 70 mg/kg as split doses over 5 days. Treatment will be observed. Drug concentrations and adverse events will be monitored. On day 1, children and their mother/guardian will be requested to stay at the health centre between 9 am and 6 pm. Fifteen children aged 2-10 years with uncomplicated P. falciparum malaria and fulfilling the inclusion criteria will be recruited into each study arm. Following the end of treatment, the children will be seen on the morning of day 7, 14, 21 and 28. Any child wishing to withdraw during the treatment phase and any child with reparasitaemia during the follow up will be given rescue treatment with arthemeter-lumefantrine or quinine according to treatment guidelines in Guinea-Bissau. Final analysis will include a description of included children, proportions of adverse events and any serious adverse events, drug concentrations and their relation to adverse events, the proportion of children withdrawn or lost to follow up, the cumulative PCR corrected and uncorrected success and failure rates on day 28 and the proportion of early, late clinical and late parasitological treatment failures.

Conditions

Interventions

TypeNameDescription
DRUGChloroquine-base 50 mg
DRUGChloroquine-base 70 mg

Timeline

Start date
2013-04-01
Primary completion
2014-02-01
Completion
2014-03-01
First posted
2013-03-20
Last updated
2014-03-11

Locations

1 site across 1 country: Guinea-Bissau

Source: ClinicalTrials.gov record NCT01814423. Inclusion in this directory is not an endorsement.